Mode
Text Size
Log in / Sign up

Fecal microbiota transplantation provides modest short-term improvements in daily motor activities for Parkinson's diseaseFecal transplant shows short term motor gains in Parkinson's disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider FMT as a safe, well-tolerated intervention for modest short-term improvements in daily motor tasks.

This meta-analysis evaluated the efficacy of fecal microbiota transplantation (FMT) delivered via oral capsules, nasojejunal tubes, or colonoscopy in patients with Parkinson's disease. The analysis included 318 patients across studies with follow-up periods ranging from 12 to 52 weeks.

The primary finding was a notable short-term enhancement in daily motor activities (MDSUPDRS Part II) after one month, with an effect size of -2.19 (95% confidence interval -4.32 to -0.06; P = 0.044). No significant estimates were noted for MDS-UPDRS Part III, aggregate MDS-UPDRS scores, motor complications, non-motor symptoms, or overall quality of life.

Authors noted several limitations, including the lack of uniform improvements in cognitive ability, anxious feelings, and constipation-related quality of life. The authors emphasize the need for more extensive, sufficiently powered trials using standardized FMT procedures and longer observation periods. Clinical evidence suggests FMT is a well-tolerated, safe treatment that may offer modest short-term advantages for motor tasks in Parkinson's disease.

How this fits prior evidence

This meta-analysis addresses a gap in non-pharmacological interventions for Parkinson's disease. While mindfulness-based exercise has been shown to improve motor function and GLP-1 receptor agonists are being explored for metabolic pathways, this finding specifically evaluates the role of FMT. The results confirm that FMT is well-tolerated but only provides evidence for short-term improvements in specific motor activities rather than broader non-motor symptoms or quality of life.

Living with Parkinson's disease often means struggling with the physical movements required for everyday life. New research looked at how fecal microbiota transplantation, or FMT, might help. This process involves transferring healthy bacteria into a patient's system through capsules, tubes, or colonoscopies to see if it improves symptoms.

The study looked at 318 patients and found that those who received the transplant saw a notable improvement in daily motor activities after just one month. While these improvements were seen in basic physical movements, the research did not find significant changes in other areas like overall quality of life, cognitive ability, or non-motor symptoms.

Safety is an important factor for any new treatment. The procedure was well tolerated by patients, with only mild and self-resolving stomach issues reported. However, because this data comes from a small group of studies, more large trials are needed to see if these benefits last longer or help with other parts of the condition.

What this means for you:
Fecal transplants may provide modest, short-term improvements in daily physical movements for Parkinson's patients.

Common questions

How does this treatment work for Parkinson's?

The treatment involves a fecal microbiota transplantation, or FMT. This means transferring healthy bacteria into the body through oral capsules, tubes, or colonoscopies. The goal is to see if these healthy microbes can help improve physical movements and daily activities for people living with Parkinson's disease.

Is it safe for patients to try?

The procedure was well tolerated by the 318 patients in the study. While some people experienced mild gastrointestinal issues, these problems were self-resolving and no serious adverse events were reported. You should talk to your doctor about whether this is a safe option for your specific needs.

Does it help with all symptoms of Parkinson's?

The study found that while there was an improvement in daily motor activities after one month, there were no significant improvements in other areas. This includes non-motor symptoms, cognitive ability, anxiety levels, or overall quality of life. More research is needed to see if it helps beyond basic movement.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up12.0 mo
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Parkinson's disease (PD) is a common neurodegenerative disease that is a growing public health challenge. Recent evidence showed that gut microbiota dysbiosis is involved in the pathogenesis of PD, prompting interest in fecal microbiota transplantation (FMT) as a potential disease-modifying intervention. This systematic review and meta-analysis aim to evaluate the efficacy and safety of FMT in patients with PD. METHODS: We conducted a systematic literature review using PubMed, Scopus, Web of Science, and the Cochrane Library till June 4, 2026, to identify RCTs comparing FMT with placebo or control interventions in PD. After removal of duplicates alongside title and abstract screening, followed by full-text screening, seven randomized controlled trials were included in this systematic review and meta-analysis. RESULTS: A total of seven randomized controlled trials (RCTs) with 318 subjects were analyzed. FMT was delivered via oral capsules, nasojejunal tubes, or colonoscopy, with follow-up periods ranging from 12 to 52 weeks. The meta-analysis indicated a notable short-term enhancement in daily motor activities, as assessed by MDSUPDRS Part II, after one month (mean difference - 2.19, 95% confidence interval - 4.32 to -0.06; P = 0.044). Nevertheless, no significant estimates were noted for MDS-UPDRS Part III, aggregate MDS-UPDRS scores, motor complications, non-motor symptoms, or overall life quality at any assessed time frame. Some individual studies reported gains in cognitive ability, anxious feelings, quality of life related to constipation, and certain PDQ-39 categories, although these improvements were not uniformly observed. Overall, FMT was well tolerated by participants, with adverse reactions mostly comprising mild, self-resolving gastrointestinal issues and no major safety risks. CONCLUSIONS: FMT is a safe treatment for individuals with PD and may offer modest short-term advantages in performing daily motor tasks. However, current evidence does not indicate lasting enhancements in overall motor capabilities, non-motor symptoms, or life quality. More extensive and sufficiently powered trials utilizing standardized FMT procedures and longer observation periods are necessary to elucidate the therapeutic benefits of FMT in Parkinson's disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.